SAN FRANCISCO -- More adults with moderate-to-severe Crohn's disease (CD) reached clinical remission after 6 months on ...
AbbVie’s Skyrizi was responsible for the highest TV advertising outlay in pharma in most months of 2024, but 2025 is starting ...
Two years after AbbVie’s loss of market exclusivity for Humira, those “How it Started and How it’s Going” memes are looking ...
Investor's Business Daily on MSN7d
AbbVie Surges 8% As Immunology Powerhouses Skyrizi And Rinvoq Continue To DominateAbbVie stock retook its 200-day moving average Friday after the company raised its long-term outlook for Skyrizi and Rinvoq ...
ABBV stock, with 24% returns since the beginning of 2024, has marginally underperformed the S&P 500 index, up 27%. An ...
Rinvoq to $31B amid Humira decline. Skyrizi hit $11.7B and Rinvoq $5.97B in 2024, while Humira fell to $9B from $14.4B in ...
AbbVie Q4 earnings beat estimates, driven by strong sales of Skyrizi and Rinvoq, with an updated 2027 combined revenue ...
Novartis issued stronger guidance than Wall Street expected. Elsewhere, Eisai and Biogen’s Alzheimer’s drug will get a closer ...
In last year's update, AbbVie raised the combined 2027 net sales guidance for Skyrizi and Rinvoq by $6 billion to $27 billion ...
AbbVie reported strong Q4 results, driven by Skyrizi, Rinvoq, neuroscience products, and eye care. Click here to find out why ...
24/7 Wall St. on MSN8d
AbbVie (ABBV) Earnings Live: Why The Stock Is Up Big TodayLive Updates Deep Dive into ABBV's Earnings Call 11:53 am Looking through AbbVie’s earnings call, these growth prospects stood out: 1. Skyrizi & Rinvoq Set to Dominate Immunology Market 2025 revenue ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback